Last updated: July 20, 2026

Does Aetna Cover ADHD Treatment in Maine? A 2026 Guide

If you have Aetna insurance in Maine and you or a family member has been diagnosed with attention-deficit/hyperactivity disorder (ADHD), understanding your coverage may save you hundreds. Or even thousands. Of dollars each year. Aetna is one of Maine’s major commercial insurers, and its pharmacy benefits are administered through CVS/Caremark. This guide explains how Maine’s mental health parity law applies to ADHD, what the CVS/Caremark formulary typically covers, which medications require prior authorization, and how Maine’s Electronic Prescribing of Controlled Substances (EPCS) rules affect your prescriptions.

Ready to connect with a licensed ADHD provider who accepts Aetna? See if your Aetna plan may cover ADHD treatment at Klarity →

Key facts at a glance

• Insurer: Aetna (Maine commercial and Medicare Advantage plans)
• PBM: CVS/Caremark
• State parity law: Me. Rev. Stat. Ann. tit. 24-A, § 2749-A (ADHD is a covered mental health condition)
• Maine EPCS: Schedule II stimulants (Adderall, Ritalin, Vyvanse, Concerta, Dexedrine) = EPCS REQUIRED. Non-stimulants (Strattera, Qelbree, Intuniv, Kapvay) are non-scheduled = EPCS inapplicable.
• PA requirement: Generic stimulants typically no PA; brand stimulants and most non-stimulants require PA + possible step therapy
• Aetna member services: 1-800-872-3862
• CVS/Caremark: 1-800-552-8159
• Maine Bureau of Insurance: 1-800-300-5000

Maine Mental Health Parity Law and ADHD Coverage

Maine’s mental health parity law. Me. Rev. Stat. Ann. tit. 24-A, § 2749-A. Requires that state-regulated commercial health insurers, including most Aetna individual and fully insured group plans sold in Maine, provide mental health and substance use disorder benefits that are no more restrictive than comparable medical/surgical benefits. ADHD is recognized as a mental health condition under the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and is subject to these parity protections.

In practical terms, § 2749-A means:

• Aetna may not impose higher copays, stricter prior authorization criteria, or lower visit limits for ADHD treatment than it does for comparable physical health conditions
• Quantitative treatment limitations (visit caps, day limits) and non-quantitative treatment limitations (medical necessity criteria, step therapy requirements) must be comparable
• If you believe Aetna is applying more restrictive criteria to your ADHD care than to analogous medical care, you have a right to request a parity analysis and file a complaint with the Maine Bureau of Insurance

Important note: § 2749-A applies to state-regulated, fully insured commercial plans. ERISA-governed self-funded employer plans are subject to the federal Mental Health Parity and Addiction Equity Act (MHPAEA) rather than Maine state law, though the substantive protections are similar.

How Aetna Covers ADHD Treatment in Maine

Aetna’s ADHD coverage typically includes the following categories of care, subject to your specific plan’s terms:

Medical/Behavioral Health Benefits

• Diagnostic evaluation: Psychiatric or psychological evaluation for ADHD diagnosis, subject to in-network copay/coinsurance
• Outpatient visits: Ongoing medication management appointments with a psychiatrist, primary care physician, or licensed prescriber
• Telehealth: Virtual ADHD evaluation and medication management visits are covered at parity with in-person visits under Maine law and Aetna’s telehealth policy
• Behavioral therapy: Individual therapy, cognitive behavioral therapy (CBT), and behavioral skills training for ADHD are typically covered as outpatient mental health benefits
• Neuropsychological testing: Comprehensive testing may be covered with prior authorization when medically necessary for diagnosis or treatment planning

Pharmacy Benefits (CVS/Caremark)

Aetna’s pharmacy benefits for ADHD medications are managed by CVS/Caremark. Coverage and cost-sharing depend on your specific plan’s formulary tier, deductible status, and any applicable prior authorization or step therapy requirements. The table below reflects typical CVS/Caremark formulary placement for common ADHD medications; always verify your specific plan’s formulary at aetna.com or by calling CVS/Caremark at 1-800-552-8159.

Formulary tiers and PA requirements are subject to change. Always verify your specific Aetna plan’s drug list before prescribing or filling a prescription.

Maine EPCS Rules for ADHD Medications

Maine has one of the broadest Electronic Prescribing of Controlled Substances (EPCS) mandates in the country. Under Maine law, EPCS is required for all Schedule II through Schedule V controlled substances. Not just Schedule II as in some states like Hawaii.

What this means for ADHD stimulant medications:

All Schedule II ADHD stimulants. Including amphetamine salts (Adderall, generic equivalents), methylphenidate (Ritalin, Concerta, generic equivalents), lisdexamfetamine (Vyvanse, generic lisdexamfetamine), dextroamphetamine (Dexedrine), and mixed amphetamine salts extended release (Mydayis). Are subject to Maine’s EPCS mandate. Prescriptions for these medications must be sent electronically by a DEA-registered, EPCS-certified prescriber. Paper prescriptions are generally not permitted except in narrow exemptions (technological failure, dispensing in a facility without internet access, etc.).

What this means for non-stimulant ADHD medications:

Non-stimulant ADHD medications. Atomoxetine (Strattera/generic), viloxazine ER (Qelbree), guanfacine ER (Intuniv/generic), and clonidine ER (Kapvay). Are not controlled substances under federal or Maine law. Maine’s EPCS mandate is entirely inapplicable to these medications. They may be prescribed electronically or on paper at the prescriber’s discretion.

Klarity and EPCS compliance:

Klarity’s licensed Maine prescribers are DEA-registered and use EPCS-certified platforms for all controlled substance prescriptions, including Schedule II ADHD stimulants. You can receive your Adderall or Ritalin prescription electronically without an in-person visit, subject to your prescriber’s clinical judgment and applicable Maine telehealth prescribing rules.

Prior Authorization for ADHD Medications Under Aetna/CVS/Caremark

Prior authorization (PA) is a process by which your insurance carrier reviews a medication before approving coverage. Under Aetna’s CVS/Caremark formulary, PA requirements for ADHD medications typically work as follows:

Medications that typically do NOT require PA:

• Generic immediate-release amphetamine salts (generic Adderall)
• Generic extended-release amphetamine salts (generic Adderall XR)
• Generic methylphenidate (immediate-release and extended-release)

Medications that typically DO require PA:

• Brand-name stimulants (Adderall XR brand, Vyvanse brand): PA + step therapy. Aetna/CVS/Caremark typically requires documented trial of a generic equivalent before approving the brand-name version unless there is a clinically documented reason the generic is inadequate (e.g., inactive ingredient allergy, demonstrated bioavailability difference).
• Generic lisdexamfetamine (generic Vyvanse): May require PA depending on plan tier; check your specific formulary.
• Atomoxetine (generic Strattera): PA required. CVS/Caremark typically requires documentation of ADHD diagnosis, clinical rationale for non-stimulant preference (e.g., stimulant intolerance, history of substance use disorder, comorbid tic disorder), and medical necessity review.
• Qelbree (viloxazine ER): PA required. As a newer branded non-stimulant, Qelbree typically requires step therapy documentation of prior stimulant or atomoxetine trial.
• Guanfacine ER / Clonidine ER: May require PA on some plans, particularly as adjunctive therapy.

PA criteria Aetna/CVS/Caremark commonly applies:

• Confirmed diagnosis of ADHD (DSM-5 criteria documented in medical record)
• Age-appropriate criteria (adult vs. pediatric dosing and formulation considerations)
• For brand medications: documented trial and failure/intolerance of the generic equivalent
• For non-stimulants: clinical rationale for non-stimulant approach when a stimulant would typically be first-line
• Prescriber specialty or documentation supporting the diagnosis for more complex presentations

Step-by-Step: How to Verify Your Aetna ADHD Coverage in Maine

1. Log in to your Aetna member portal at aetna.com. Navigate to “Benefits” → “Pharmacy” → “Drug Cost & Coverage Tool.” Enter your specific ADHD medication to see your plan’s tier, estimated cost, and any PA requirements.
2. Call Aetna member services at 1-800-872-3862. Ask specifically: (a) Is [medication name] covered under my plan? (b) What tier is it on? (c) Is prior authorization required? (d) Are there step therapy requirements? Request a Reference Number for the call.
3. Call CVS/Caremark at 1-800-552-8159 to verify pharmacy benefit details and confirm EPCS requirements for any Schedule II stimulant prescription.
4. Confirm your provider is in-network. Aetna’s network includes physicians, psychiatrists, nurse practitioners, and physician assistants. Klarity’s Maine providers can be verified at aetna.com/find-a-doctor.
5. Request a Summary of Benefits and Coverage (SBC) if you are unsure of your exact plan terms. Your employer HR department or Aetna member services can provide this document.

What to Do If Aetna Denies Your ADHD Claim or PA Request

If Aetna denies coverage, a PA request, or a step therapy exception for an ADHD medication, you have the right to appeal. Maine law and Aetna’s internal appeals process provide a structured pathway:

1. Request the denial letter in writing. Aetna must provide a written explanation of the denial, including the specific clinical criteria applied and the plan provision cited. You have the right to request the full clinical guidelines used to make the decision.
2. Peer-to-peer review. Your prescribing provider may request a peer-to-peer call with Aetna’s medical director or reviewing clinician. This is often the fastest way to overturn a PA denial and should be the first step for clinical disputes.
3. File a formal internal appeal. Under Maine law, Aetna must resolve non-urgent appeals within 30 calendar days and urgent/expedited appeals within 72 hours. Submit clinical documentation: diagnosis records, treatment history, letter of medical necessity from your provider, and any supporting literature.
4. Request a parity analysis. If the denial involves ADHD medication management and you believe Aetna would not impose the same restrictions on a comparable physical health condition, request a written parity analysis under § 2749-A. File a parity complaint with the Maine Bureau of Insurance if the analysis reveals a disparity.
5. External Independent Medical Review (IMR). If Aetna upholds the denial after your internal appeal, you have the right to request an external IMR by an independent review organization certified by the Maine Bureau of Insurance. Aetna must comply with the IMR decision.

Maine Bureau of Insurance: 1-800-300-5000 | maine.gov/pfr/insurance
U.S. Department of Labor EBSA (for ERISA plans): 1-866-444-3272

Get Started with Aetna-Accepted ADHD Treatment in Maine

Klarity connects Maine residents with licensed ADHD providers. Including psychiatrists, nurse practitioners, and physician assistants. Who are experienced with Aetna coverage and CVS/Caremark PA requirements. Our providers are EPCS-certified and can send Schedule II stimulant prescriptions electronically in compliance with Maine law.

• 100% telehealth. No commute, no waiting room
• Initial evaluation and ongoing medication management available
• Providers who understand Maine’s § 2749-A parity protections and can support PA appeals with clinical documentation
• 2,000+ licensed providers nationwide, including Maine-licensed clinicians

Check if your Aetna plan may cover ADHD treatment at Klarity →

Frequently Asked Questions

Does Aetna cover telehealth ADHD treatment in Maine?

Aetna typically covers telehealth ADHD evaluation and medication management at parity with in-person visits. Maine law requires parity for telehealth mental health services. Coverage details vary by plan; verify with Aetna at 1-800-872-3862 before your first appointment.

Does Aetna cover Vyvanse (lisdexamfetamine) in Maine?

Generic lisdexamfetamine (the generic for Vyvanse) may be covered at Tier 2. 3 under CVS/Caremark’s formulary with possible PA requirements. Brand-name Vyvanse is typically Tier 3. 4 and requires PA plus documented step therapy. Your prescriber can submit a PA request with clinical documentation of medical necessity.

Can I get an Adderall prescription through telehealth in Maine?

Yes. Maine allows telehealth prescribing of Schedule II ADHD stimulants including amphetamine salts (Adderall) by DEA-registered, EPCS-certified providers, subject to applicable clinical and prescribing standards. The prescription must be sent electronically under Maine’s EPCS mandate.

What if Aetna denies coverage for my ADHD medication?

You may request a peer-to-peer review (provider calls Aetna’s medical reviewer), file a formal internal appeal within Aetna’s 30-day non-urgent / 72-hour urgent timeline, or escalate to an external Independent Medical Review through the Maine Bureau of Insurance. A parity complaint under § 2749-A may also be appropriate if the denial appears more restrictive than comparable medical/surgical benefit decisions.

Does Aetna cover non-stimulant ADHD medications like Strattera or Qelbree?

Atomoxetine (generic Strattera) and viloxazine ER (Qelbree) may be covered under Aetna’s pharmacy benefit with prior authorization. Non-stimulants are not controlled substances, so Maine’s EPCS mandate does not apply. PA criteria typically require documentation of ADHD diagnosis and clinical rationale for choosing a non-stimulant approach.

Is Aetna required to cover ADHD treatment under Maine parity law?

Yes, for state-regulated commercial plans. Me. Rev. Stat. Ann. tit. 24-A, § 2749-A requires Aetna to cover mental health conditions. Including ADHD. At parity with comparable medical/surgical conditions. This means copays, PA criteria, and visit limits for ADHD care may not be more restrictive than those for analogous physical health benefits. ERISA self-funded employer plans are subject to the federal MHPAEA rather than Maine state law.

Key Contacts

• Aetna member services: 1-800-872-3862
• CVS/Caremark pharmacy benefits: 1-800-552-8159
• Maine Bureau of Insurance: 1-800-300-5000
• Maine DHHS Behavioral Health: 1-800-977-6740
• U.S. DOL EBSA (ERISA plans): 1-866-444-3272
• CMS (Medicare/Medicaid questions): 1-800-633-4227

Coverage disclaimer: Insurance coverage for ADHD treatment varies by Aetna plan type, employer group, and individual benefit design. The information in this article reflects typical coverage patterns and Maine regulatory requirements as of July 2026, but does not constitute a guarantee of coverage. Always verify your specific benefits with Aetna and CVS/Caremark before scheduling an appointment or filling a prescription. Klarity Health is not affiliated with Aetna or CVS/Caremark.